---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-134769"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:07:58.725047+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences Q1 net loss $31.6M; cash $180.9M; pipeline milestones on track

## Summary
- Q1 revenue $12.5M (vs $12.9M YoY); net loss $31.6M (vs $27.4M). Cash $180.9M; plus $12M from GSK milestone in April.
- RestorAATion-2 for AATD underway; proof-of-mechanism data expected in 2024.
- INHBE obesity program targets 1Q 2025 trial start; preclinical weight loss similar to semaglutide with fat loss, no muscle loss.
- FORWARD-53 DMD 24-week dystrophin data expected 3Q 2024; SELECT-HD multi-dose data expected 2Q 2024.
- Appointed Dr. Erik Ingelsson as CSO to drive genetic target discovery; GSK advanced two programs triggering $12M payment.

## SEC filing metadata
- accession: 0001193125-24-134769
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312524134769/0001193125-24-134769-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312524134769/d813742d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-134769
- JSON: https://secwatch.observer/filing/0001193125-24-134769.json
- Plain text: https://secwatch.observer/filing/0001193125-24-134769.txt

## Key facts
- Earnings Releases
  Wave Life Sciences Ltd. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 9, 2024, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1631574/000119312524134769/0001193125-24-134769-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.